Payment overview · 2025
General Payments
$1,287.26
69 reported records · 15 companies
Healthcare provider profile · identity verified
Kenneth Ackerman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT NECK, NY · NPI 1033205265
Verified facts
What the public records show
CMS Open Payments records show Kenneth Ackerman, M.D. received $1,287.26 in general payments during 2025 across 69 reported records.
Novo Nordisk Inc accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $291.90 | 22.7% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.41 | 19.8% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.59 | 14.3% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $170.70 | 13.3% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.17 | 8.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.01 | 3.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.60 | 3.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.48 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.51 | 2.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.11 | 2.0% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $23.85 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.08 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.65 | 1.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $18.16 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,287.26 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $218.00 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $164.21 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $154.72 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $151.26 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $120.67 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $120.67 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $120.67 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.10 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.92 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.92 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.02 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $43.01 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.41 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.41 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
120 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 393 | 117 |
| Zolpidem Tartrate | Zolpidem Tartrate | 363 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 126 |
| Alprazolam | Alprazolam | 311 | 90 |
| Omeprazole | Omeprazole | 282 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 58 |
| Metformin Hcl | Metformin Hcl | 174 | 54 |
| Meloxicam | Meloxicam | 172 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 165 | 119 |
| Famotidine | Famotidine | 161 | 53 |
| Azithromycin | Azithromycin | 151 | 126 |
| Simvastatin | Simvastatin | 144 | 51 |
| Losartan Potassium | Losartan Potassium | 138 | 47 |
| Trazodone Hcl | Trazodone Hcl | 133 | 28 |
| Synthroid | Levothyroxine Sodium | 120 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 43 |
| Sertraline Hcl | Sertraline Hcl | 117 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 42 |
| Celecoxib | Celecoxib | 103 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 39 |
| Diazepam | Diazepam | 100 | 28 |
| Allopurinol | Allopurinol | 97 | 31 |
| Gabapentin | Gabapentin | 93 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 24 |
| Azelastine Hcl | Azelastine Hcl | 80 | 46 |
| Mounjaro | Tirzepatide | 79 | suppressed |
| Glimepiride | Glimepiride | 75 | 18 |
| Montelukast Sodium | Montelukast Sodium | 71 | 34 |
| Finasteride | Finasteride | 69 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 36 |
| Cefdinir | Cefdinir | 67 | 60 |
| Methylprednisolone | Methylprednisolone | 67 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 12 |
| Ozempic | Semaglutide | 62 | 11 |
| Clonazepam | Clonazepam | 61 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 59 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 33 |
| Metformin Hcl Er | Metformin Hcl | 56 | 15 |
| Furosemide | Furosemide | 54 | 15 |
| Lisinopril | Lisinopril | 54 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Spironolactone | Spironolactone | 53 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Lactulose | Lactulose | 52 | 18 |
| Ramipril | Ramipril | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 22 |
| Atenolol | Atenolol | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 14 |
| Prednisone | Prednisone | 47 | 18 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | 12 |
| Mupirocin | Mupirocin | 44 | 24 |
| Tramadol Hcl | Tramadol Hcl | 44 | 16 |
| Cefuroxime | Cefuroxime Axetil | 41 | 37 |
| Irbesartan | Irbesartan | 41 | 11 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 17 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 20 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Cefadroxil | Cefadroxil | 33 | 28 |
| Meclizine Hcl | Meclizine Hcl | 33 | 20 |
| Telmisartan | Telmisartan | 33 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 19 |
| Colchicine | Colchicine | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Valacyclovir | Valacyclovir Hcl | 27 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Lidocaine | Lidocaine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 12 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxaprozin | Oxaprozin | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,287.26 · 69 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, ELIQUIS, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error